Navigation Links
Watson Confirms Cenestin(R) Patent Challenge
Date:4/26/2010

pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health.  Watson has operations in many of the world's established and growing international markets.

For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

Forward-Looking Statement

Statements contained in this press release that refer to non-historical facts are forward-looking statements that reflect Watson's current perspective of existing information as of the date of this release.  It is important to note that Watson's goals and expectations are not predictions of actual performance. Actual results may differ materially from Watson's current expectations depending upon a number of factors affecting Watson's business. These factors include, among others, the difficulty of predicting the timing or outcome of product development efforts and FDA approvals or actions, if any; the difficulty of predicting the timing or outcome of litigation; the impact of competitive products and pricing; the timing and success of product launches; difficulties or delays in manufacturing; the availability and pricing of third party sourced products and materials; successful compliance with FDA and other governmental regulations applicable to Watson and its third party manufacturers' facilities, products and/or businesses; changes in the laws and regulations, including Medicare and Medicaid, affecting among other things, pricing and reimbursement of pharmaceutical products; and such other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including b
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Watson Launches Generic Biaxin(R) XL
2. Watson Announces Positive Results From Its Pivotal Study of Oxybutynin Topical Gel for the Treatment of Overactive Bladder
3. Watson Announces Silodosin NDA Accepted for Filing by FDA for the Treatment of Benign Prostatic Hyperplasia
4. Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder
5. Watson Announces United States Availability of RAPAFLO(TM) (silodosin), a Novel New Treatment in Benign Prostatic Hyperplasia (BPH)
6. Watson and Barr Settle Lawsuit Over Oxytrol(R)
7. Watson to Host Conference Call and Webcast to Discuss Fourth Quarter 2009 Earnings and 2010 Outlook
8. Watson Completes Acquisition of Eden Biodesign
9. Watson to Present at Credit Suisse Healthcare Conference
10. Watson Announces New Program to Help Promote Good Bone Health in Advanced Prostate Cancer Patients on Long-Term Androgen Deprivation Therapy
11. Watson Files FDA Application for Generic Rozerem(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Manufacturers, suppliers and ... be able to protect their most important business ... http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because of the ... steadfastly remains one of the most litigious industry ...
(Date:1/15/2014)... 2014 Tegra Medical is very pleased to announce the ... new Chief Executive Officer.  Mark was promoted from his current ... the company,s four facilities in Massachusetts , ... joined Tegra Medical in 2012 with 20+ years of broad-based ...
(Date:1/15/2014)... Therapeutics, Inc. (Nasdaq: ECTE ) ("Echo"), a ... a non-invasive, wireless continuous glucose monitoring system, today announced ... Interim CEO of Echo Therapeutics, will present at "TEN", ... Mr. Doman will make a corporate presentation ...
Breaking Medicine Technology:Intellectual Property Insurance for Medical-related Products and Services 2Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3
... 31, 2011 Leading events organiser UBM Live ... details of a new Logistics and Supply Chain Zone ... to pharmaceutical contract services and outsourcing. ICSE will take ... Germany and is part of the world,s leading platform ...
... (NASDAQ: UPI ), announced today that the ... (NICE) issued guidance on percutaneous tibial nerve stimulation (PTNS) ... NICE issued similar guidance on PTNS treatment for overactive ... in the UK and Europe to use our Urgent® ...
Cached Medicine Technology:Logistics and Supply Chain Zone Introduced at ICSE 2011 Event 2Logistics and Supply Chain Zone Introduced at ICSE 2011 Event 3United Kingdom's National Institute for Health and Clinical Excellence Issues Guidance on Percutaneous Tibial Nerve Stimulation for Faecal Incontinence 2
(Date:7/10/2014)... 2014 Up to 70% of Parkinson,s disease ... their quality of life. Some patients have disturbed ... staying asleep, while other patients may be subject ... the extreme, PD patients may exhibit REM-sleep behavior ... dream re-enactment, even before motor symptoms appear. A ...
(Date:7/10/2014)... of Huddersfield could help to improve the quality of ... such as butter, mayonnaise, yoghurt and fruit drinks ... for her work. , Katerina gained her MSc degree ... now she has embarked on research for a PhD. ... is investigating the potential of carbohydrates extracted from the ...
(Date:7/10/2014)... 2014) A research review identifying the clinical indicators ... step in the process of developing evidence-based guidelines for ... report published by Neurosurgery , official ... . The journal is published by Lippincott Williams ... Kluwer Health . , Based on analysis of ...
(Date:7/10/2014)... decades, health-conscious people around the globe have taken antioxidant ... was one of the paths to good health and ... of antioxidant supplements have repeatedly dashed the hopes of ... risk. Virtually all such trials have failed to ... in several trials antioxidant supplementation has been linked with ...
(Date:7/10/2014)... the Bellvitge Biomedical Research Institute (IDIBELL) and the Catalan ... patients a new therapeutic combination to combat resistant sarcomas. ... treatment could stabilize the growth of these tumors have ... of Cancer ., Sarcomas , Sarcomas are a ... several subtypes. It can affect from children to older ...
Breaking Medicine News(10 mins):Health News:Sleep disturbances, common in Parkinson's disease, can be early indicator of disease onset 2Health News:World interest in research work on the benefits of the Okra plant 2Health News:What's a concussion? Review identifies four evidence-based indicators 2Health News:What's a concussion? Review identifies four evidence-based indicators 3Health News:How antioxidants can accelerate cancers, and why they don't protect against them 2Health News:New therapeutic combination to slow resistant sarcomas 2
... five-year international clinical study shows that acyclovir, a commonly prescribed ... not affect HIV transmission by people with both viruses. ... Transmission Study, was released by the New England Journal ... will follow in the print edition Feb. 4. ...
... ... Second Wave of H1N1 Flu: No Waiting in Long Lines , ... San Diego, Calif. (Vocus) January 25, 2009 -- U.S. ... nation, announced today that they are offering H1N1 vaccine shots for $15 per shot for ...
... for surgery than county hospitals, research shows , MONDAY, ... received by prostate cancer patients is influenced by the ... a new U.S. study has found. , Surgery was ... while patients in private facilities were more likely to ...
... , ROCHESTER, Minn. , Jan. ... the brain is the aim of a new Mayo Clinic project ... The new method uses analytics technology developed by the Mayo and ... 95 percent accuracy rate in detecting aneurysms, compared with 70 percent ...
... , NEW YORK , ... of the 25 largest PR firms ( http://www.5wpr.net/ ) in the U.S., today ... its versatile roster of fashion and lifestyle clients. Launched in 2002, the luxury ... lifestyle products using proprietary natural frequency technology. , " Philip Stein is ...
... CHESAPEAKE, Va. , Jan. 25 U.S.-based, Maison ... Haiti -based Maison Fortune Orphanage. The strategic expansion plans ... after the recent devastating earthquakes. The Orphanage, located near the ... in a sea of unimaginable turmoil. , This planned expansion ...
Cached Medicine News:Health News:Control of herpes symptoms does not reduce HIV transmission, international study found 2Health News:U.S. HealthWorks in San Diego Region Offering $15 H1N1 Vaccinations for both Walk-Ins and On-Site 2Health News:Prostate Cancer Care Varies By Hospital Type 2Health News:Mayo Clinic and IBM Advance Early Detection of Brain Aneurysms 2Health News:Mayo Clinic and IBM Advance Early Detection of Brain Aneurysms 3Health News:Mayo Clinic and IBM Advance Early Detection of Brain Aneurysms 4Health News:5W Public Relations Adds Philip Stein Watches to Its Fashion & Lifestyle Client Roster 2Health News:5W Public Relations Adds Philip Stein Watches to Its Fashion & Lifestyle Client Roster 3Health News:Haitian Orphanage Takes Quick Action to Fill Void after Devastating Earthquakes 2Health News:Haitian Orphanage Takes Quick Action to Fill Void after Devastating Earthquakes 3
Provides immediate access to comprehensive coverage of more than 325 I.V. drugs, blood products, and solutions....
... a comprehensive, authoritative drug reference to ... overdose management, Canadian drug names, OTC ... drug references and tools is included ... (ED, PRIMARY CARE PLUS, CRC, RN, ...
... patients and health consumers from the trusted ... in MedMaster includes why the medication is ... side effects and warning signs of adverse ... information on what to do if a ...
Provides reliable information on the most commonly prescribed drugs, their side effects, interactions and cost of therapy....
Medicine Products: